Natera, Inc. $NTRA Shares Bought by ASR Vermogensbeheer N.V.

ASR Vermogensbeheer N.V. lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 621.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,374 shares of the medical research company’s stock after purchasing an additional 10,658 shares during the quarter. ASR Vermogensbeheer N.V.’s holdings in Natera were worth $2,090,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of Jackson Hole Trust acquired a new stake in shares of Natera during the 1st quarter worth approximately $29,000. Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Natera during the 2nd quarter worth approximately $36,000. Rakuten Securities Inc. raised its position in shares of Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock worth $31,000 after purchasing an additional 119 shares during the period. TCTC Holdings LLC raised its position in shares of Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after purchasing an additional 124 shares during the period. Finally, ORG Partners LLC acquired a new stake in shares of Natera during the 1st quarter worth approximately $32,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Saturday, September 27th. Royal Bank Of Canada set a $268.00 price target on Natera and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Morgan Stanley restated an “overweight” rating and issued a $195.00 target price on shares of Natera in a research report on Sunday, August 10th. Cowen restated a “buy” rating on shares of Natera in a research report on Friday, August 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $192.88.

Natera Stock Up 4.5%

NTRA opened at $167.35 on Friday. The firm has a market cap of $22.97 billion, a PE ratio of -87.62 and a beta of 1.74. The business has a fifty day simple moving average of $161.17 and a 200-day simple moving average of $156.61. Natera, Inc. has a fifty-two week low of $117.27 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business’s revenue was up 32.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Michael Burkes Brophy sold 2,491 shares of the firm’s stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $162.05, for a total value of $403,666.55. Following the completion of the sale, the chief financial officer owned 69,189 shares of the company’s stock, valued at $11,212,077.45. This trade represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Rowan E. Chapman sold 2,750 shares of the firm’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the sale, the director directly owned 6,015 shares of the company’s stock, valued at approximately $1,004,444.85. This trade represents a 31.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,464 shares of company stock valued at $10,963,125 over the last quarter. 5.63% of the stock is owned by insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.